Meta’s (META) latest earnings report sent shockwaves through Wall Street on Thursday, with shares falling more than 10% as investors balked at the company’s growing AI investments. ...
Avadel Pharmaceuticals’ $2.1B acquisition by Alkermes underscores Lumryz’s strong growth and profitability, with added upside tied to FDA approval for a new sleep disorder indication. ...
Nvidia (NVDA) has just become the first company in history to cross the $5 trillion market capitalization mark, a feat that highlights its leading position in the AI infrastructure race ...
Avanos Medical’s sale of its Game Ready unit to WRS Group sharpens focus on core pain and nutrition lines, streamlining operations and sparking fresh acquisition interest. ...
Datavault AI’s expansion with new hubs in Philadelphia, Georgia, and London signals bold growth as it scales data monetization tech following 467% YoY gains and a key IBM partnership. ...
Gigacloud Technology’s acquisition of New Classic Home Furnishing boosts its sourcing network and U.S. reach, signaling strategic growth and supply-chain diversification amid global trade volatility. ...
Viomi Technology’s $20M share buyback through 2027 signals confidence post major restructuring and renewed focus on home water systems, sparking investor optimism despite lingering small-cap risks. ...
Qualcomm (QCOM) soared over than 20% on Monday after the chipmaker announced a bold new plan to enter the data center AI market. ...
Clear Channel Outdoor soars 27% after reports that Abu Dhabi’s Mubadala Capital may pursue a takeover. Despite heavy debt, the small-cap billboard firm draws investor interest amid sale speculation. ...
Beyond Meat crashes below $1 for the first time, marking a 99% drop from its peak. A massive debt swap, plunging sales, and fading plant-based demand leave the onetime food ...
Neogen Corporation shares jumped 23% after solid Q1 results and a new cost-cutting plan that trims 10% of its workforce, signaling a focused turnaround under new leadership after a tough ...
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds. ...